Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Timing matters: sex differences in treatment limitation decisions in intensive care.

Critical care (London, England)·2026
Same author

Ratio of Left Atrial and Ventricular Volume as New Marker of Atrial Cardiopathy and Stroke Risk.

Stroke·2026
Same author

Neural resilience improves survival in cardiovascular patients.

Cardiovascular research·2026
Same author

Bidirectional brain-heart interactions in health and disease.

Nature reviews. Neurology·2026
Same author

Decoding sex and gender effects on health: evidence from a nationwide cohort.

Biology of sex differences·2026
Same author

The junctional protein associated with coronary artery disease predicts adverse cardiovascular events in patients with acute coronary syndromes at high residual risk.

European heart journal·2025

Related Experiment Video

Updated: May 10, 2026

Flow Cytometry Analysis of Tissue Factor Expression in Human Platelets
10:08

Flow Cytometry Analysis of Tissue Factor Expression in Human Platelets

Published on: November 22, 2024

Caffeic acid phenethyl ester inhibits endothelial tissue factor expression.

Cathérine Gebhard1, Barbara Elisabeth Stähli, Stephanie Largiadèr

  • 1Cardiovascular Research, Physiology Institute, University of Zürich, Zürich, Switzerland.

Biological & Pharmaceutical Bulletin
|June 4, 2013
PubMed
Summary

Caffeic acid phenethyl ester (CAPE) found in honeybee hives can reduce blood clot formation. CAPE inhibits tissue factor (TF) protein expression and activity, showing potential as an anti-thrombotic agent.

More Related Videos

Extracellular Vesicle Tissue Factor Activity Assay
03:53

Extracellular Vesicle Tissue Factor Activity Assay

Published on: December 29, 2023

Extraction and Purification of Polyphenols from Freeze-dried Berry Powder for the Treatment of Vascular Smooth Muscle Cells In Vitro
12:00

Extraction and Purification of Polyphenols from Freeze-dried Berry Powder for the Treatment of Vascular Smooth Muscle Cells In Vitro

Published on: July 5, 2017

Related Experiment Videos

Last Updated: May 10, 2026

Flow Cytometry Analysis of Tissue Factor Expression in Human Platelets
10:08

Flow Cytometry Analysis of Tissue Factor Expression in Human Platelets

Published on: November 22, 2024

Extracellular Vesicle Tissue Factor Activity Assay
03:53

Extracellular Vesicle Tissue Factor Activity Assay

Published on: December 29, 2023

Extraction and Purification of Polyphenols from Freeze-dried Berry Powder for the Treatment of Vascular Smooth Muscle Cells In Vitro
12:00

Extraction and Purification of Polyphenols from Freeze-dried Berry Powder for the Treatment of Vascular Smooth Muscle Cells In Vitro

Published on: July 5, 2017

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Pharmacology

Background:

  • Tissue factor (TF) is a key initiator of thrombosis and is expressed in human endothelial cells.
  • Caffeic acid phenethyl ester (CAPE), a honeybee hive component, possesses various beneficial properties.
  • Understanding CAPE's effect on TF expression is crucial for exploring its anti-thrombotic potential.

Purpose of the Study:

  • To investigate the effect of CAPE on tumor necrosis factor (TNF)-α induced tissue factor (TF) expression in human aortic endothelial cells (HAECs).

Main Methods:

  • Human aortic endothelial cells (HAECs) were treated with varying concentrations of CAPE.
  • Western blot analysis was used to assess TF protein expression.
  • Real-time polymerase chain reaction (PCR) was employed to evaluate TF mRNA levels.
  • TF promoter activity and mitogen-activated protein (MAP) kinase activation were also examined.

Main Results:

  • CAPE significantly inhibited TNF-α induced TF protein expression in a dose-dependent manner.
  • CAPE treatment led to a reduction in TF surface activity.
  • No significant alterations were observed in TF mRNA expression, TF promoter activity, or MAP kinase activation.

Conclusions:

  • CAPE exerts its anti-thrombotic effect by inhibiting TF protein expression and activity at the posttranscriptional level.
  • These findings highlight CAPE's potential as a therapeutic agent for preventing thrombosis.